{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:53Z","timestamp":1792785053422,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Iran University of Medical Sciences","award":["26344"],"award-info":[{"award-number":["26344"]}],"id":[{"id":"https:\/\/ror.org\/03w04rv71","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-61681-6","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:47:29Z","timestamp":1784112449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of an in-house one-step RT-qPCR method for the quantification of the BCR::ABL1 p210 transcripts"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1602-8572","authenticated-orcid":false,"given":"Fatemeh","family":"Damerchiloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8967-3167","authenticated-orcid":false,"given":"Fatemeh","family":"Karamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8759-6120","authenticated-orcid":false,"given":"Ali","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2684-1014","authenticated-orcid":false,"given":"Mehrnoosh","family":"Shanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9663-9313","authenticated-orcid":false,"given":"Mahmood","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0070-6620","authenticated-orcid":false,"given":"Majid","family":"Safa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"61681_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-016-0108-0","volume":"35","author":"Z-J Kang","year":"2016","unstructured":"Kang, Z.-J. et al. The Philadelphia chromosome in leukemogenesis. Chin. J. Cancer 35, 1\u201315 (2016).","journal-title":"Chin. J. Cancer"},{"issue":"5","key":"61681_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani, M. et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33(5), 1173\u20131183 (2019).","journal-title":"Leukemia"},{"issue":"11","key":"61681_CR3","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2025","unstructured":"Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am. J. Hematol. 99(11), 2191\u20132212 (2025).","journal-title":"Am. J. Hematol."},{"issue":"7","key":"61681_CR4","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1038\/bcj.2017.62","volume":"7","author":"Z Gong","year":"2017","unstructured":"Gong, Z. et al. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 7(7), e583 (2017).","journal-title":"Blood Cancer J."},{"issue":"3","key":"61681_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ijlh.12616","volume":"39","author":"A Arun","year":"2017","unstructured":"Arun, A. et al. Frequency of rare BCR\u2010ABL 1 fusion transcripts in chronic myeloid leukemia patients. Int. J. Lab. Hematol. 39(3), 235\u2013242 (2017).","journal-title":"Int. J. Lab. Hematol."},{"issue":"11","key":"61681_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NC Cross","year":"2023","unstructured":"Cross, N. C. et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia 37(11), 2150\u20132167 (2023).","journal-title":"Leukemia"},{"key":"61681_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155161","volume":"254","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani, M. et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol. Res. Pract. 254, 155161 (2024).","journal-title":"Pathol. Res. Pract."},{"issue":"12","key":"61681_CR8","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1586\/14737140.2013.859074","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour, E. J., Cortes, J. E. & Kantarjian, H. M. Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev. Anticancer Ther. 13(12), 1433\u20131452 (2013).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"61681_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-025-01292-y","volume":"15","author":"SS J\u00f8nsson","year":"1995","unstructured":"J\u00f8nsson, S. S. et al. Temporal changes in survival among adult patients with chronic myeloid leukemia in the period 1995\u20132022\u2014A Danish nationwide population-based register study. Blood Cancer J. 15(1), 1\u20134 (1995).","journal-title":"Blood Cancer J."},{"issue":"11","key":"61681_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994\u20131004 (2003).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"61681_CR11","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford, S. et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112(8), 3330\u20133338 (2008).","journal-title":"Blood"},{"issue":"1","key":"61681_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah, N. P. et al. Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 22(1), 43\u201369 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"10","key":"61681_CR13","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"N Cross","year":"2012","unstructured":"Cross, N., White, H., M\u00fcller, M., Saglio, G. & Hochhaus, A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10), 2172\u20132175 (2012).","journal-title":"Leukemia"},{"issue":"8","key":"61681_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080697","volume":"11","author":"P Kwa\u015bnik","year":"2021","unstructured":"Kwa\u015bnik, P. & Giannopoulos, K. Treatment-free remission\u2014A new aim in the treatment of chronic myeloid leukemia. J. Pers. Med. 11(8), 697 (2021).","journal-title":"J. Pers. Med."},{"issue":"6","key":"61681_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele, S. et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 19(6), 747\u2013757 (2018).","journal-title":"Lancet Oncol."},{"issue":"3","key":"61681_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne, G. et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J. Clin. Oncol. 35(3), 298\u2013305 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"61681_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DMBS Ross","year":"2013","unstructured":"Ross, D. M. B. S. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 122(4), 515\u2013522 (2013).","journal-title":"Blood."},{"key":"61681_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi, N. et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: The JALSG-STIM213 study. Int. J. Hematol. 107, 185\u2013193 (2018).","journal-title":"Int. J. Hematol."},{"issue":"5","key":"61681_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NC Cross","year":"2015","unstructured":"Cross, N. C. et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29(5), 999\u20131003 (2015).","journal-title":"Leukemia"},{"issue":"6","key":"61681_CR20","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-024-02252-4","volume":"38","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Measurable residual disease (MRD)-testing in haematological and solid cancers. Leukemia 38(6), 1202\u20131212 (2024).","journal-title":"Leukemia"},{"issue":"19","key":"61681_CR21","first-page":"1578","volume":"134","author":"J Radich","year":"2019","unstructured":"Radich, J., Yeung, C. & Wu, D. New approaches to molecular monitoring in CML (and other diseases). Blood, J. American Soc. Hematol. 134(19), 1578\u20131584 (2019).","journal-title":"Blood, J. American Soc. Hematol."},{"issue":"7","key":"61681_CR22","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark, R. E. et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): A non-randomised, phase 2 trial. Lancet Haematol. 6(7), e375\u2013e383 (2019).","journal-title":"Lancet Haematol."},{"issue":"5","key":"61681_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot, P. et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J. Clin. Oncol. 32(5), 424\u2013430 (2014).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"61681_CR24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus, A. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4), 966\u2013984 (2020).","journal-title":"Leukemia"},{"issue":"4","key":"61681_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jmoldx.2019.03.002","volume":"21","author":"JT Brown","year":"2019","unstructured":"Brown, J. T. et al. Analytical validation of a highly sensitive, multiplexed chronic myeloid leukemia monitoring system targeting BCR-ABL1 RNA. J. Mol. Diagn. 21(4), 718\u2013733 (2019).","journal-title":"J. Mol. Diagn."},{"issue":"21","key":"61681_CR26","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1182\/blood.V122.21.2617.2617","volume":"122","author":"J Toplin","year":"2013","unstructured":"Toplin, J. et al. Development and validation of highly sensitive Mrdx BCR-ABL test for monitoring deep molecular response in patients with chronic myeloid leukemia. Blood 122(21), 2617 (2013).","journal-title":"Blood"},{"issue":"9","key":"61681_CR27","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","volume":"53","author":"ES Winn-Deen","year":"2007","unstructured":"Winn-Deen, E. S. et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin. Chem. 53(9), 1593\u20131600 (2007).","journal-title":"Clin. Chem."},{"issue":"2","key":"61681_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2353\/jmoldx.2007.060112","volume":"9","author":"Z Jobbagy","year":"2007","unstructured":"Jobbagy, Z., van Atta, R., Murphy, K. M., Eshleman, J. R. & Gocke, C. D. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J. Mol. Diagn. 9(2), 220\u2013227 (2007).","journal-title":"J. Mol. Diagn."},{"issue":"1","key":"61681_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3343\/alm.2020.40.1.72","volume":"40","author":"H-J Chung","year":"2020","unstructured":"Chung, H.-J. et al. Performance evaluation of the QXDx BCR-ABL% IS droplet digital PCR assay. Ann. Lab. Med. 40(1), 72\u201375 (2020).","journal-title":"Ann. Lab. Med."},{"issue":"2","key":"61681_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jmoldx.2024.11.003","volume":"27","author":"C Kockerols","year":"2025","unstructured":"Kockerols, C., Valk, P. J., Hogenbirk, P., Cornelissen, J. J. & Westerweel, P. E. BCR:: ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using a US Food and Drug Administration\u2013approved droplet-based digital PCR assay. J. Mol. Diagn. 27(2), 109\u2013118 (2025).","journal-title":"J. Mol. Diagn."},{"issue":"6","key":"61681_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000496","volume":"4","author":"CC Kockerols","year":"2020","unstructured":"Kockerols, C. C. et al. Digital PCR for BCR-ABL1 quantification in CML: Current applications in clinical practice. Hemasphere 4(6), e496 (2020).","journal-title":"Hemasphere"},{"issue":"1","key":"61681_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes, T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1), 28\u201337 (2006).","journal-title":"Blood"},{"issue":"6","key":"61681_CR33","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6), 872\u2013884 (2013).","journal-title":"Blood"},{"issue":"2","key":"61681_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/leu.2014.217","volume":"29","author":"H White","year":"2015","unstructured":"White, H. et al. A certified plasmid reference material for the standardisation of BCR\u2013ABL1 mRNA quantification by real-time quantitative PCR. Leukemia 29(2), 369\u2013376 (2015).","journal-title":"Leukemia"},{"issue":"3","key":"61681_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","volume":"22","author":"NC Cross","year":"2009","unstructured":"Cross, N. C. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract. Res. Clin. Haematol. 22(3), 355\u2013365 (2009).","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"22","key":"61681_CR36","first-page":"e111","volume":"116","author":"HE White","year":"2010","unstructured":"White, H. E. et al. Establishment of the first World Health Organization international genetic reference panel for quantitation of BCR-ABL mRNA. Blood, J. American Soc. Hematol. 116(22), e111\u2013e117 (2010).","journal-title":"Blood, J. American Soc. Hematol."},{"issue":"6","key":"61681_CR37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","volume":"59","author":"HE White","year":"2013","unstructured":"White, H. E. et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin. Chem. 59(6), 938\u2013948 (2013).","journal-title":"Clin. Chem."},{"issue":"9","key":"61681_CR38","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/leu.2016.90","volume":"30","author":"NC Cross","year":"2016","unstructured":"Cross, N. C. et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia 30(9), 1844\u20131852 (2016).","journal-title":"Leukemia"},{"issue":"9","key":"61681_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22612","volume":"32","author":"Y Fu","year":"2018","unstructured":"Fu, Y. et al. Development and evaluation of armored RNA-based standards for quantification of BCR-ABL 1p210\/p190 fusion gene transcripts. J. Clin. Lab. Anal. 32(9), e22612 (2018).","journal-title":"J. Clin. Lab. Anal."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61681-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61681-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61681-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:59:06Z","timestamp":1792061946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61681-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61681"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61681-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Committee of Iran University of Medical Sciences provided ethical endorsement for this research study (agreement number IR.IUMS.REC.1402.368). Written informed consent was obtained from all participants for publication of the details of their medical cases before the study.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for participation was obtained from all participants. No identifiable personal information is presented in this manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32407"}}